---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-087808"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2026-07-29T11:06:13+00:00"
generated_at: "2026-07-29T11:10:14.693338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure reports Q2 net loss $81.1M; AMT-130 BLA submission on track for Q3 2026

## Summary
- Net loss $81.1M ($1.22/share) vs $37.7M ($0.69) in Q2 2025; revenue $5.8M (+$0.5M).
- Cash $810.3M after $259M June offering; runway into 2030.
- AMT-130 BLA submission for Huntington's on track for Q3 2026; four-year data expected Sept 2026.
- AMT-260 Phase I/IIa: 3 of 6 patients had 79-100% seizure reduction; no SAEs related to drug.
- AMT-191 Fabry data: dose-dependent α-Gal A activity up to 229.6x normal; all 11 patients off ERT.

## SEC filing metadata
- accession: 0001104659-26-087808
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2026-07-29T11:06:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/0001104659-26-087808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-087808
- JSON: https://secwatch.observer/filing/0001104659-26-087808.json
- Plain text: https://secwatch.observer/filing/0001104659-26-087808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.